盐酸替罗非班对急性心肌梗死细胞因子的影响  

Effect on Serum Levels of Cytokine in Patients with AMI Treated by Tirofiban

作　　者：陈小亮[1] 刘向儒[1] 唐春仕[1] 李世煌[1] 

机构地区：[1]湖南省郴州市第一人民医院心内科,423000

出　　处：《中华全科医学》2013年第10期1559-1559,1594,共2页Chinese Journal of General Practice

摘　　要：目的探讨盐酸替罗非班联合PCI对急性心肌梗死(AMI)患者血清MIF、IL-10的影响。方法将78例AMI患者随机分为治疗及对照组,均予常规溶栓及PCI治疗,治疗组加用盐酸替罗非班,首先10.0μg/kg静脉推注,然后以0.15μg/(kg·min)持续静脉滴注24 h。ELISA法检测各组治疗前后血清MIF、IL-10水平。并检测各组心功能各项指标。结果两组患者治疗后血清MIF水平均下降、IL-10水平均升高(P<0.05),心功能亦明显改善,但治疗组更为显著(P<0.05),且其总有效率显著高于对照组(P<0.05)。结论盐酸替罗非班可能通过调节抗炎反应平衡,改善AMI介入治疗患者的心功能,疗效满意。Objective To investigate the effect on serum levels of MIF,IL-IO in patients with AMI treated by Tirofiban. Methods 78 AMI patients were randomly divided into treatment and control group. They were all given conventional thrombolytic drug and PCI treatment, and treatment group was added with Tirofiban. In two groups, the serum levels of MIF and IL-10 were detected by ELISA. Results The level of MIF decreased, while IL-10 increased in two groups （ P 〈 0.05 ）. And SV, CO, CI, LVEF decreased, while LVEDD, LVESD increased in two groups （ P 〈 0.05 ）. But all index of treatment group improved more significantly（ P 〈 0.05 ）. Conclusion Tirofiban may modulate anti-inflammatory reaction equilibrium and improve cardiac function in AMI patients treated by PCI.

关 键 词：盐酸替罗非班 冠脉介入治疗 急性心肌梗死 巨噬细胞移动抑制因子 白介素-10 

分 类 号：R542.22[医药卫生—心血管疾病] R972[医药卫生—内科学]